afterpains
Conditions
Interventions
Experimental Group (High-intensity Group):The current intensity is adjusted to the maximum level that the patient can tolerate (above the sensory threshold, with a strong tingling sensation but no pai
Control group (low-intensity group):The device will output a perceptible current within the first 30 seconds (to convince the patient that the treatment has begun), and then automatically reduce to be
Sponsors
The First Affiliated Hospital of Naval Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Full-term pregnant women (=37 weeks) who delivered vaginally or by cesarean section; 2) Age: 18 to 45 years old; 3) Voluntarily participate in this experiment and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Severe pregnancy complications (such as eclampsia, placental abruption); 2) History of implanted cardiac pacemaker or epilepsy; 3) Long-term use of analgesics or chronic pain history; 4) Depression scale, anxiety scale = 50 points (Self-Rating Anxiety Scale/Self-Rating Depression Scale score below 50 points is normal; 50-60 points is mild anxiety; 61-70 points is moderate anxiety; over 70 points is severe anxiety); 5) Other pain-related diseases; 6) Skin damage, dermatitis, infection or abnormal sensation in the area where the electrode patches are attached; 7) Known allergy to electrical stimulation or other contraindications for TENS treatment; 8) Cognitive impairment or mental illness, unable to cooperate with the research assessment; 9) Currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The peak pain Visual Analogue Scale (VAS) within 72 hours.; | — |
Secondary
| Measure | Time frame |
|---|---|
| pain intensity;Number of occurrences and frequency of pain;Heart rate at each time point;Galvanic skin response;Short Form McGill Pain Questionnaire;PSQI Score;Rescue Analgesia Rate;First rescue analgesia time;Morphine-equivalent daily dose;Postpartum Recovery Status;Serum ß-endorphin, Substance P, Prostaglandin F2a;Heart Rate Variability;Uterine involution status;Adverse Event; | — |
Countries
China
Contacts
Public ContactJin Yu
The First Affiliated Hospital of Naval Medical University
Outcome results
None listed